Characterization of Differences Between Prostate Cancer Patients Presenting With De Novo Versus Primary Progressive Metastatic Disease
Author:
Publisher
Elsevier BV
Subject
Urology,Oncology
Reference20 articles.
1. Cancer Statistics, 2017;Siegel;CA Cancer J Clin,2017
2. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement;Moyer;Ann Intern Med,2012
3. Cancer treatment and survivorship statistics, 2016;Miller;CA Cancer J Clin,2016
4. Increasing incidence of metastatic prostate cancer in the United States (2004-2013);Weiner;Prostate Cancer Prostatic Dis,2016
5. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period;Wu;Cancer,2014
Cited by 38 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Prognostic value of germline mutations in metastatic hormone-sensitive prostate cancer (mHSPC);Urologic Oncology: Seminars and Original Investigations;2024-10
2. Metastatic hormone-naïve prostate cancer: a distinct biological entity;Trends in Cancer;2024-09
3. The Neutrophil-to-Lymphocyte Ratio as a Biomarker in Metastatic Castrate-Sensitive Prostate Cancer Patients Treated with Abiraterone Acetate;Société Internationale d’Urologie Journal;2024-08-20
4. The transcriptional landscape of metastatic hormone-naïve prostate cancer;2024-05-21
5. Identifying Suitable Patients for Overcoming Androgen Deprivation Monotherapy in De Novo Metastatic Hormone-Sensitive Prostate Cancer;Journal of Personalized Medicine;2024-05-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3